January/February 2021 Newsletter |
|
In This Issue:
- President's Message
- Board of Director's Update
- R&E Foundation Update
- 2020 Annual Survey Results
- Public Policy Update
- 2021 ICHP/MSHP Spring Meeting
- Pharmacist Continuing Education Articles
- Review of Semaglutide, the First Oral GLP-1 Receptor Agonist
- Brexanolone for the Treatment of Postpartum Depression
- Featured Clinical Topic: Endocrinology
- Pharmacogenomics of Diabetes Mellitus
- New Glucagon Products for Severe Hypoglycemia: Gvoke® and Baqsimi®
- Insulin Considerations and Comparisons for Pediatric and Adolescent Diabetic Populations
- Affiliate Chapter News and Events
- Upcoming Newsletter Info
|
|
By Davina Dell-Steinbeck, PharmD, BCPS; SSM Health St. Mary’s Hospital
|
“Legacy is not what I did for myself. It’s what I am doing for the next generation.”
-Vitor Belfort
“People have been known to achieve more as a result of working with others than against them.”
-Allan Fromme
One of my favorite things that I do every year is attend the MSHP Spring Meeting. I love the networking and the learning. I enjoy catching up with old friends, students, and colleagues and meeting new people. I am amazed when I walk through the poster sessions with the awesome research that is being done throughout the state. I always leave the meeting feeling rejuvenated and full of new ideas that I would like to implement at my own practice site.
|
|
Board of Director's Update |
|
By Christina Stafford, PharmD, BCPS- MSHP President- Elect; CoxHealth, Springfield
November
- The 2020-2021 budget was approved by the Board
- Presidential Officers Retreat is this week
- ASHP MidYear is 100% virtual
- The Missouri Board of Pharmacy is planning to develop legislation to allow pharmacy technicians to administer COVID-19 and pediatric vaccines in Missouri
- Call for House of Delegates- call will be sent out before Thanksgiving
- Midyear Reception- plan is to conduct a virtual awards ceremony for the Clinical Skills Competition winners in lieu of a reception
December
- Ashley Duty and Allison King had recent publications
- Call for award nominations for Spring Meeting coming soon
- Call for Board nominations coming soon
- House of Delegates- email vote to be sent out in January
- Working on providing information to educate pharmacists on vaccination
- The board voted to approve the strategic plan with the following updates:
- Extend timeline for NPW to develop six education webinars to 2022
- Extend deadline for fundraising to 2022
- Davina and Alex signed onto a letter requesting the Biden Transition Team make the current temporary telehealth flexibility permanent
|
|
By: Megan Musselman, Pharm.D, MS, BCPS, BCCCP; MSHP Research and Education Foundation Board Member |
What a year! While we did not get to meet in person for the ASHP Midyear, I hope you all had a wonderful meeting and a Happy New Year. This year at the ASHP Virtual Midyear Missouri Reception we awarded the Clinical Skills Competition winners from STLCOP and UMKC. Lauren Spreen and Paige Lemasters represented STLCOP at the Clinical Skills Competition at Midyear this year. From UMKC, Connor Foxhoven and Rebecca Adt represented their school. Congratulations for their hard work!!
In addition to providing financial support to these pharmacy students for their participation in the ASHP Virtual Midyear Clinical Skills Competition, the R&E Foundation also provides several awards at the MSHP/ICHP Spring Meeting.
It is hard to believe but the 2021 MSHP/ICHP Spring Meeting is just around the corner. If you have not marked your calendar yet, please do so for March 18-20, 2021. The R&E Foundation has an exciting new event to announce this year - we will be hosting a virtual trivia night. This is the moment you have all been waiting for! Now is the time to brush off your shoes, play some light practice games of trivial pursuit, and work on your reflexes to improve your response times before the big match! A good time, bragging rights and the opportunity to show off your random knowledge is guaranteed.
|
|
2020 Annual Survey Results |
|
By: Kristin Peterson, PharmD, BCPS, BCCP – MSHP Membership Committee Chair; Mercy Hospital Joplin |
The Membership Committee is pleased to share some of the results from the 2020 MSHP Annual Survey. This year 64 members responded to the survey.
Reasons for Being Involved
Affiliate chapter activities and CE was selected by respondents as the primary reason for involvement in MSHP.
Top three reasons for being involved in MSHP:
- Affiliate chapter activities and continuing education
- MSHP meetings and continuing education
- Networking
|
|
Focus on the Possible
By Nathan Hanson, PharmD, MS, BCPS, Health Trust Supply Chain
|
|
We are in the People Business.
Every day, we go to work to take care of people. Pharmacists are in the business of protecting, educating, persuading, and serving people. It’s what we do, as we interact with patients, nurses, doctors, and other health care professionals. Today I’d like to ask for your help in educating, persuading, and serving a different group of people: Lawmakers!
|
|
2021 ICHP/MSHP Spring Meeting |
|
Please join us March 19 & 20, 2021 for the 2021 ICHP/MSHP virtual Spring Meeting!
This year's meeting offers 21.75 contact hours (2.175 CEUs) for pharmacists and 12.5 contact hours (1.25 CEUs) for pharmacy technicians. We've also got a great student session planned!
Some of the topics featured at this year's meeting:
- Advancing Pharmacy Technicians
- Pharmacy Practice in Public Health
- 2021 Healthcare Legislation and Advocacy
- Psychological Safety
- COVID-19
- and more!
|
|
Review of Semaglutide, the First Oral GLP-1 Receptor Agonist
By: Rachel Kiehne, PharmD; PGY2 Ambulatory Care Resident
Mentor: Justinne Guyton, PharmD, BCACP, PGY2 Ambulatory Care Residency Director and Associate Professor, St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis/St. Louis County Department of Public Health
|
There is a growing need for new and innovative drugs due to the significant prevalence, morbidity, and mortality of type 2 diabetes mellitus. In 2018, 32.6 million people in the United States had this disease, and diabetes mellitus was the seventh leading cause of death.1 The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical practice for the treatment of type 2 diabetes mellitus has steadily increased over the past few years due to its unique mechanism of action, efficacy, and effect on major adverse cardiac events.
Program Number: 2021-01-04
Approval Dates: February 3, 2021 to August 1, 2021
Approved Contact Hours: 1 hour
|
|
Brexanolone for the Treatment of Postpartum Depression
By: Bridgette McCauley, PharmD; PGY-2 Psychiatry Pharmacy Practice Resident
Mentor: O. Greg Deardorff, PharmD, BCPP; Clinical Pharmacy Manager, Fulton State Hospital – Fulton, MO
|
|
Postpartum depression (PPD) is classified as a major depressive disorder occurring “during pregnancy or within four weeks following delivery.”1 In the United States, the prevalence of PPD is estimated to be 11.5% and is the leading cause of maternal mortality.2-5 Within the first-year after giving birth, one in seven deaths is a result of suicide.6 Those at highest risk of developing PPD are those with a history of depression, history of or current tobacco use, have experienced domestic violence, fear childbirth, are of lower socioeconomic status, have gestational diabetes, ≥40 years old, adolescents, unintentional pregnancy, or maternal anxiety.7-12 While the etiology is not clear, there are a few theories thought to cause PPD.
Program Number: 2021-01-03
Approval Dates: February 3, 2021 to August 1, 2021
Approved Contact Hours: 1 hour
|
|
Featured Clinical Topic: Endocrinology
|
|
Pharmacogenomics of Diabetes Mellitus
By: Miriam Bisada, PharmD Candidate 2021 and Yostena Khalil, PharmD Candidate 2022; St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis.
Mentor: Erica F. Crannage, Pharm.D., FCCP, BCPS, BCACP; Associate Professor, St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis; Clinical Pharmacist Mercy Clinic-Family Medicine
|
Diabetes mellitus is a disease of abnormal carbohydrate metabolism related to relative or absolute impairment in insulin secretion. Pharmacogenomics, the study of drug responses impacted by genes, is a drastically growing field especially after the Human Genome Project (HGP) mapped DNA for the entire human genome in 2000. However, the clinical utilization of pharmacogenomics has been limited to severe idiosyncratic adverse drug reactions, variations in drug metabolism, and chemotherapy interventions.1 The International Diabetes Foundation estimated 463 million in the world were diagnosed with diabetes in 2019 and predicted 578 million by 2030.2
|
|
New Glucagon Products for Severe Hypoglycemia: Gvoke® and Baqsimi®
By: Abbey Jin, PharmD Candidate 2021, St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Mentor: Laura Challen, PharmD, MBA, BCPS, BCACP, Associate Professor, St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis; Clinical Pharmacist, JFK Clinic Mercy Hospital-St. Louis
|
Severe hypoglycemia, a severe and potentially fatal event that requires intervention, has historically been treated with injectable glucagon that requires reconstitution prior to injection. Baqsimi® and Gvoke® are new United States Food and Drug Administration (FDA)-approved glucagon products for severe hypoglycemia that provide alternative preparations. Eli Lilly and Company’s Baqsimi® nasal powder is an intranasal glucagon delivery device, approved on July 24th, 2019.1 It is the first non-injectable glucagon therapy for emergency treatment in severe hypoglycemia.1 Xeris Pharmaceutical’s Gvoke® is a glucagon injection for treatment of severe hypoglycemia, approved on September 10th, 2019.2
|
|
Insulin Considerations and Comparisons for Pediatric and Adolescent Diabetic Populations
By: Hannah Michael, PharmD, PGY1 Pharmacy Resident – University of Missouri Health Care
|
|
Current guideline therapy provided by the American Diabetes Association and the International Society for Pediatric and Adolescent Diabetes (ISPAD) highlights that type 1 diabetes accounts for most diabetic diagnoses for children and adolescents.1-3 Due to the pharmacokinetic differences of the available types of insulins and highly variable pharmacodynamics in the pediatric population, data on these regimens are not transferable from the adult population to pediatric patients. Knowing this, it is important to highlight effective insulin treatment for this population as well as the differences in administration considerations to provide the most appropriate therapeutic regimens for all age groups with diabetes. |
|
Greater Kansas City Society of Health-System Pharmacists (GKCSHP)
Mid-Missouri Society of Health-System Pharmacists (MMSHP)
Saint Louis Society of Health-System Pharmacists (STLSHP)
Southeast Missouri Society of Health-System Pharmacists (SEMSHP)
|
|
Upcoming Featured Clinical Topics
-
Mar/Apr 2021 – Psych/Neuro/Pain
-
May/June 2021 – CriticalCare/Pulm/EmergencyMed
-
July/Aug 2021 - Cardiology/Anticoagulation
-
Sept/Oct 2021 - Transitions of Care/Geriatrics
-
Nov/Dec 2021 - Infectious Diseases/Vaccines
|
|
Newsletter Submission Deadlines:
Mar/Apr 2021 - February 22nd, 2021
May/June 2021 - April 26th, 2021
July/Aug 2021 - Jun 21st, 2021
Sept/Oct 2021 - August 23rd, 2021
Nov/Dec 2021 - October 25th, 2021
|
|
Newsletter Submission Guidelines
- Pharmacists, pharmacy technicians, and pharmacy students in Missouri are eligible to submit content for publication in the MSHP Newsletter. Student submissions need to include pharmacist oversight.
- Submit content to the current Newsletter Committee Chair on or before the established deadlines.
- CE and Featured Clinical Topics must be approved by the Newsletter Committee Chair in advance of article submission, to prevent duplicates. Duplicate articles submitted without advanced approval may not be published.
- Recommended length of submissions for committee, affiliate, college/schools of pharmacy, and student chapter reports is half to one page in length.
- Recommended length of submissions for featured clinical topics is 1 to 2 pages, without references.
- Recommended length of CE articles is individualized, based on the amount of CE provided.
- Recommended length of submission for other categories is 1 to 2 pages.
|
|
MSHP Board of Directors & Committee Chairs |
|
|
|
2020-2021 Committee Chairs
|
|
If you have any questions, comments, or wish to submit an article to for MSHP Newsletter, please contact the Newsletter Committee Chair (Sarah Cook) or another Newsletter Committee member.
2020-2020 MSHP Newsletter Committee Members
|
|
|
|
|
|
|
